James Fox is Director at GenMark Diagnostics, Inc. (GNMK). They have made 5 open-market trades across 2 companies since 2012, most recently 2021-04-22.
CIK 0001500591
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $514K since 2012, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GNMK | BUY | 2020-03-06 | 2020-03-10 | $5.50 | $50K | -7.3% | +6.1% | +57.8% |
| GNMK | BUY | 2015-10-30 | 2015-11-02 | $6.90 | $83K | -8.4% | +0.4% | -30.3% |
| BOTA | BUY | 2015-06-10 | 2015-06-15 | $2.03 | $142K | N/A | N/A | N/A |
| BOTA | BUY | 2015-06-09 | 2015-06-11 | $1.99 | $139K | N/A | N/A | N/A |
| GNMK | BUY | 2012-06-26 | 2012-06-28 | $4.20 | $100K | -8.4% | +0.4% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.